Thomas h. pedersen, CEO
Thomas H. Pedersen has an academic background in skeletal muscle physiology and neuromuscular disease. He holds a PhD in Physiology from Aarhus University and he did two years of post doctoral work at Cambridge University. Thomas has years of experience in cellular electrophysiology and he has published more than 30 high-ranking papers including a first author paper in Science and several papers in The Journal of General Physiology. NMD Pharma was founded on scientific discoveries obtained in the Muscle Laboratory at Aarhus University in which Thomas holds a position as Associate Professor.
claus E. olesen, CBo
Claus Olesen has a PhD in Physiology and Biophysics from Aarhus University. His academic work focus on structural biology and function of membrane proteins and he has several publications including two first author papers in Science and Nature. Claus has been involved in several drug development projects in both academic and industrial settings. He is co-founder of Pcovery ApS and he is CEO of Initiator Pharma. Claus serves as Business Developer at Aarhus University. He is former professional sailor and he competed in Americas Cup for Sweden in 2003 and represented Denmark at two Olympics.
Patrick Vink, Chairman
Patrick Vink has more than 30 years of experience in life sciences industry. He was COO of Cubist Inc and served as Senior Vice-President of global Institutional Business at Mylan. Earlier he was head of the global business unit Biologics at Sandoz, Head of international operations at Biogen and head of worldwide Cardio-vascular and Thrombosis marketing at Sanafi-Synthelabo. Patrick is an advisor to the Life Science Industry, Chairman of Acacia Pharma, Targovax Oy and member of the Board of several publicly listed companies. Patrick is MD from University of Leiden and holds a MBA from University of Rochester and Rotterdam.
ANJA HARMEIER, BOD
Anja is an Investment Manager at the Roche Venture Fund in Basel. She is a member of the board of directors of Macrolide Pharmaceuticals, Opsona Therapeutics, Minoryx Therapeutics and NMD Pharma. Anja has experience in various roles in academic research, as an entrepreneur, and in drug development at F. Hoffmann- La Roche Ltd. Anja lead various programs using different modalities in the areas of neuroscience, metabolic diseases and in rare diseases.
Anja holds an MSc in Biology from the Technical University of Munich and earned her PhD from the Free University of Berlin in Biochemistry studying the neurotoxicity of Amyloid beta and its prevention. In addition, Anja got her MBA with a focus on healthcare management from Instituto Empresa (IE) in Madrid.
Christian E. Elling, Bod
Christian joined Lundbeckfonden in 2012 and leads early stage biotech investment unit Lundbeckfonden Emerge. He is a member of the board of directors of IO Biotech, NMD Pharma, CEO of Insusense Therapeutics and former member of the board of directors of EpiTherapeutics and Inagen. Christian was co-founder, Vice President of Biology and Development and later CEO of 7TM Pharma. Christian holds a PhD in Biochemistry and Pharmacology from University of Copenhagen, Denmark. Christian has published more than twenty papers and reviews.
LUCAS DE BREED, BOD
Lucas de Breed is currently Director at Inkef Capital, where he joined in 2013. He brings over a decade of international experience in all phases of drug development, from pre-clinical stage start-ups to brand strategy and life cycle management for Top 10 Large Pharma. In his previous role at Deallus Consulting, he was responsible for their global oncology business and founded/managed the firm’s New York City office. In addition to NMD Pharma, Lucas currently serves on the Board of Directors for TM3 Therapeutics, Scenic Biotech and InteRNA Technologies.
Lucas holds a Ph.D. from University College London for research conducted at the LRI (now Francis Crick Institute), and an MBA from Stanford University. He has also co-authored several scientific papers.
Morten G. Døssing, BOD
Morten joined Novo Seeds in 2016 as Investment Director. Prior to Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. At Lundbeck Morten led acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Morten holds an MSc in Human Biology from the University of Copenhagen.